Who Generates More Revenue? Dr. Reddy's Laboratories Limited or Travere Therapeutics, Inc.

Dr. Reddy's vs. Travere: A Decade of Revenue Growth

__timestampDr. Reddy's Laboratories LimitedTravere Therapeutics, Inc.
Wednesday, January 1, 201413217000000028203205
Thursday, January 1, 201514818900000099892000
Friday, January 1, 2016154708000000133591000
Sunday, January 1, 2017140809000000154937000
Monday, January 1, 2018142028000000164246000
Tuesday, January 1, 2019153851000000175338000
Wednesday, January 1, 2020174600000000198321000
Friday, January 1, 2021189722000000227490000
Saturday, January 1, 2022214391000000212018000
Sunday, January 1, 2023245879000000145238000
Monday, January 1, 2024279164000000
Loading chart...

Unleashing the power of data

Revenue Showdown: Dr. Reddy's vs. Travere Therapeutics

In the competitive landscape of the pharmaceutical industry, revenue generation is a key indicator of a company's market position and growth potential. Over the past decade, Dr. Reddy's Laboratories Limited has consistently outperformed Travere Therapeutics, Inc. in terms of revenue. From 2014 to 2023, Dr. Reddy's revenue surged by approximately 111%, reaching a peak in 2023, while Travere's revenue showed a modest increase of around 415% over the same period, albeit from a much smaller base.

A Decade of Growth

Dr. Reddy's Laboratories, a global pharmaceutical giant, has demonstrated robust growth, with revenues climbing steadily each year. In contrast, Travere Therapeutics, a smaller player, has experienced fluctuating revenues, with a notable peak in 2021. The data for 2024 is incomplete, highlighting the need for ongoing analysis to understand future trends.

This comparison underscores the diverse strategies and market dynamics influencing these two companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025